TGTX - Company ID 0001001316
The table below shows TG THERAPEUTICS, INC.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $616.29M | $329.00M | $233.66M | $2.79M | $6.69M | $152.00K |
| Cost of revenue | $100.71M | $38.49M | $14.13M | $265.00K | $790.00K | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $160.22M | $94.29M | $76.19M | $125.35M | $222.58M | $165.90M |
TG THERAPEUTICS, INC. reported annual revenue of $616.29M for fiscal year 2025. That is up 87.3% from $329.00M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $152.00K (FY 2016) to $616.29M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $232.03M |
| $154.30M |
| $122.71M |
| $95.48M |
| $128.09M |
| $107.85M |
| Operating income | $123.32M | $41.93M | $20.63M | -$218.32M | -$344.77M | -$273.59M |
| Income tax | -$339.79M | $2.21M | $390.00K | $0.00 | $0.00 | $0.00 |
| Net income | $447.20M | $23.40M | $12.70M | -$198.30M | -$348.10M | - |
| EPS (diluted) | $2.77 | $0.15 | $0.09 | -$1.65 | -$2.63 | -$2.42 |